<< How Domperidone Stops Nausea and Vomiting

Friend & Foe Foods for Sufferers Of Gastroparesis >>

Domperidone - Keeping Abreast of the Controversies

September 6, 2011 by Estella     0

Controversy- Interracial Couples
Controversy- Interracial Couples
The British Columbia Drug and Poison Information Centre (DPIC) has posted an article titled Domperidone - Keeping Abreast of the Controversies on their website. The article, written by Karen Wlock, B.Sc. (Pharm), is in response to frequent questions received by the Canadian organization about the use of prescription domperidone for breastfeeding.

The DPIC is affiliated with the BC Centre for Disease Control in Vancouver, BC, and is staffed by physicians, pharmacists and nurses who are experts in the area of drugs and poisons.

Wlock discusses the health and legal issues around using domperidone for lactation, and addresses the FDA domperidone controversy. Although domperidone is widely used around the world (and is even available over the counter in many countries), the FDA has yet to approve its use in the US, citing "safety concerns" about possible cardiac irregularities associated with high doses of intravenous domperidone.

Wlock reviews studies and articles around the safety profile and reported side effects of domperidone, noting that there is only one reported case of possible cardiotoxicity associated with oral (as opposed to intravenous) domperidone therapy. The case was in an infant, whose EKG returned to normal within one month of discontinuing therapy.

She concludes that the risk of adverse cardiac events at common therapeutic doses of oral domperidone is low. To read the in-depth article on the DPIC website, >CLICK HERE.<

Filed under: FDA and Domperidone.

Tags: prescription domperidone, domperidone for breastfeeding, domperidone for lactation, FDA domperidone, side effects of domperidone, domperidone dose, domperidone therapy, domperidone in canada.

Leave your comment:

Your email address will not be published. Required fields are marked with *.

Name (required, limit 30 characters)

Email (required, will not be published)

Your Comment

Enter Code (not case-sensitive)